Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:AnthimIndication |
treatment of inhalational anthrax
prevention of inhalational anthrax |
| gptkbp:CEO |
Elizabeth Posillico
|
| gptkbp:developedBy |
gptkb:obiltoxaximab
|
| gptkbp:focusesOn |
infectious disease therapeutics
|
| gptkbp:foundedIn |
1998
|
| gptkbp:fundedBy |
gptkb:Biomedical_Advanced_Research_and_Development_Authority
gptkb:U.S._Department_of_Health_and_Human_Services |
| gptkbp:headquartersLocation |
gptkb:Parsippany,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Elusys Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Anthim
|
| gptkbp:receivedFDAApprovalFor |
gptkb:Anthim
|
| gptkbp:specializesIn |
antitoxins
|
| gptkbp:website |
https://www.elusys.com/
|
| gptkbp:bfsParent |
gptkb:obiltoxaximab
|
| gptkbp:bfsLayer |
8
|